| FORM 8-K: MABVAX THERAPEUTICS HOLDINGS, INC FILES Current report
US Official News, April 6, 2015 Monday
MABVAX THERAPEUTICS HOLDINGS, INC, Delaware, has filed FORM 8-K (Current report) with Securities and Exchange Commission on April 06, 2015 State or other Jurisdiction of Incorporation: Delaware Item 1.01 Entry into a Material Definitive Agreement. Private Placement As of April 3, 2015, MabVax Therapeutics Holdings, Inc. (the “Company”) entered into separate subscription agreements (the “Subscription Agreement”) with accredited investors (the “Investors”) relating to the issuance and sale of $11,614,501 of units (the “Units”) at a purchase price of $0.75 per Unit, with each Unit consisting of one share of the Company’s common stock, par value $0.01 per share (the “Common Stock”) (or, at the election of any Investor who, as a result of receiving Common Stock would hold in excess of 4.99% of the Company’s issued and outstanding Common Stock, shares of the Company’s newly designated 0% Series E Convertible Preferred Stock (the “Preferred Shares”)) and a thirty month warrant (the “Warrants”) to purchase one half of one share of Common Stock at an initial exercise price of $1.50 per share (such sale and issuance, the “Private Placement”). The Preferred Shares are governed by a Certificate of Designations, Preferences and Rights of the 0% Series E Convertible Preferred Stock (the “Certificate of Designations”) as described herein. The Company conducted an initial closing of the Private Placement on March 31, 2015 in which it sold an aggregate of $4,995,750 of Units.